⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNXP News
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
globenewswire.com
TNXP
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
globenewswire.com
TNXP
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
globenewswire.com
TNXP
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
globenewswire.com
TNXP